<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EDROPHONIUM CHLORIDE</span><br/>(ed-roe-foe'nee-um)<br/><span class="topboxtradename">Enlon, </span><span class="topboxtradename">Reversol, </span><span class="topboxtradename">Tensilon<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">cholinergic (parasympathomimetic) cholinesterase inhibitor</span><br/><b>Prototype: </b>Neostigmine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Indirect-acting cholinesterase inhibitor similar to neostigmine that is rapidly reversible. Acts as antidote to curariform
         drugs by displacing them from muscle cell receptor sites, thus permitting resumption of normal transmission of neuromuscular
         impulses. Like neostigmine, it prolongs skeletal muscle relaxant action of succinylcholine chloride and decamethonium bromide.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Acts as antidote to curariform drugs by displacing them from muscle cell receptor sites, thus permitting resumption of normal
         transmission of neuromuscular impulses.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Differential diagnosis and as adjunct in evaluation of treatment requirements of myasthenia gravis, for differentiating myasthenic
         from cholinergic crisis, and to reverse neuromuscular blockade produced by overdosage of nondepolarizing skeletal muscle relaxants,
         e.g., tubocurarine, gallamine. Not recommended for maintenance therapy in myasthenia gravis because of its short duration
         of action.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To terminate paroxysmal atrial tachycardia, as an aid in diagnosing supraventricular tachyarrhythmias, and to evaluate function
         of demand pacemakers.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to anticholinesterase agents; intestinal and urinary obstruction. Safety during pregnancy (category C) or
         lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Bronchial asthma; cardiac arrhythmias; patients receiving digitalis.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Edrophonium Test for Myasthenia Gravis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> Prepare 10 mg in a syringe; inject 2 mg over 1530 sec, if no reaction after 45 sec, inject the remaining 8 mg, may repeat
               test after 30 min <span class="rdroute">IM</span> Inject 10 mg, if cholinergic reaction occurs, retest after 30 min with 2 mg to rule out false-negative reaction<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span>
<i><img src="../images/special/lesserorequal.gif"/>34 kg,</i> 1 mg, if no response after 45 sec, dose may be titrated up to 5 mg <span class="rdroute">IM</span> 2 mg <span class="rdroute">IV</span>
<i>&gt;34 kg,</i> 2 mg, if no response after 45 sec, dose may be titrated up to 10 mg <span class="rdroute">IM</span> 5 mg<br/><span class="rdage">Infant:</span> <span class="rdroute">IM</span> 0.51 mg<br/><br/><span class="indicationtitle">Evaluation of Myasthenia Treatment</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 mg administered 1 h after last PO dose of anticholinesterase medication<br/><br/><span class="indicationtitle">Curare Antagonist</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 10 mg administered over 3045 sec, may repeat q510 min as needed up to 40 mg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Have antidote (atropine sulfate) immediately available and facilities for endotracheal intubation, tracheostomy, suction,
            assisted respiration, and cardiac monitoring for treatment of cholinergic reaction.
            			
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> May be given undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span>
<small>USE</small> for diagnosis of MGInject 2 mg (adult &amp; child &gt;34 kg) or 1 mg (child <img src="../images/special/lesserorequal.gif"/>34
                  kg) over 1530 sec; if no reaction after 45 sec, inject additional 8 mg (adult) or titrate up to a total of 8 mg additional
                  (child &gt;34 kg) or titrate in 1 mg increments up to a total of 4 mg additional (child <img src="../images/special/lesserorequal.gif"/>34
                  kg), may repeat test after 30 min. If cholinergic reaction (increased muscle weakness) is obtained after initial 1 or 2 mg,
                  discontinue test and give atropine IV (as ordered).  
               </p>
<ul>
<li>
                     						Note: Some clinicians recommend giving a 12 mg test dose of edrophonium to older adult patients, to those with history of
                     heart disease or who take digitalis, and possibly to all patients.
                     					
                  </li>
</ul>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Severe adverse effects uncommon with usual doses. <span class="typehead"> CNS:</span> Weakness, muscle cramps, dysphoria, fasciculations, incoordination, dysarthria, dysphagia, convulsions, <span class="speceff-life">respiratory paralysis</span>. <span class="typehead">CV:</span> Bradycardia, irregular pulse, hypotension, pulmonary edema. <span class="typehead">Special Senses:</span> Miosis, blurred vision, diplopia, lacrimation. <span class="typehead">GI:</span> Diarrhea, abdominal cramps, nausea, vomiting, excessive salivation. <span class="typehead">Respiratory:</span> Increased bronchial secretions, <span class="speceff-life">bronchospasm, laryngospasm</span>, pulmonary edema. <span class="typehead">Other:</span> Excessive sweating, urinary frequency, incontinence. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Procainamide,</b>
<b>quinidine</b> may antagonize the effects of edrophonium; <span class="classification">digitalis glycosides</span> increase the sensitivity of the heart to edrophonium; <b>succinylcholine,</b>
<b>decamethonium</b> may prolong neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  3060 sec IV; 210 min IM. <span class="typehead">Duration:</span> 510 min IV; 530 min IM. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs. Observe for signs of respiratory distress. Patients &gt;50 y are particularly likely to develop bradycardia,
            hypotension, and cardiac arrest.
         </li>
<li>Edrophonium test for myasthenia gravis: All cholinesterase inhibitors (anticholinesterases) should be discontinued for at
            least 8 h before test. Positive response to edrophonium test consists of brief improvement in muscle strength unaccompanied
            by lingual or skeletal muscle fasciculations.
         </li>
<li>Evaluation of myasthenic treatment: <i>Myasthenic response</i> (immediate subjective improvement with increased muscle strength, absence of fasciculations; generally indicates that patient
            requires larger dose of anticholinesterase agent or longer-acting drug); <i>Cholinergic response</i> [muscarinic adverse effects (lacrimation, diaphoresis, salivation, abdominal cramps, diarrhea, nausea, vomiting; accompanied
            by decrease in muscle strength; usually indicates over-treatment with cholinesterase inhibitor)]; <i>Adequate response</i> [no change in muscle strength; fasciculations may be present or absent; minimal cholinergic adverse effects (observed in
            patients at or near optimal dosage level)].
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>